{"url_path":"/sec/bblgw/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1419554/0001493152-26-023163-index.html","accession_number":"0001493152-26-023163","cik":"0001419554","ticker":"BBLG","issuer_name":"Bone Biologics Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1419554/0001493152-26-023163-index.html","primary_entity_key":"0001419554","primary_entity_name":"Bone Biologics Corp"},"word_count":1573,"has_tables":true,"body_markdown":"false\nQ1\n--12-31\n0001419554\n\n0001419554\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:CommonStock0.001ParValuePerShareMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:WarrantsToPurchaseCommonStock0.001ParValuePerShareMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\n2026-05-14\n\n0001419554\n\n2026-03-31\n\n0001419554\n\n2025-12-31\n\n0001419554\n\n2025-01-01\n2025-03-31\n\n0001419554\n\nus-gaap:CommonStockMember\n\n2025-12-31\n\n0001419554\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-12-31\n\n0001419554\n\nus-gaap:RetainedEarningsMember\n\n2025-12-31\n\n0001419554\n\nus-gaap:CommonStockMember\n\n2024-12-31\n\n0001419554\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-12-31\n\n0001419554\n\nus-gaap:RetainedEarningsMember\n\n2024-12-31\n\n0001419554\n\n2024-12-31\n\n0001419554\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nus-gaap:RetainedEarningsMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001419554\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-01\n2025-03-31\n\n0001419554\n\nus-gaap:RetainedEarningsMember\n\n2025-01-01\n2025-03-31\n\n0001419554\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001419554\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0001419554\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0001419554\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0001419554\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0001419554\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0001419554\n\n2025-03-31\n\n0001419554\n\n2025-06-05\n2025-06-05\n\n0001419554\n\nus-gaap:CertificatesOfDepositMember\n\n2026-03-31\n\n0001419554\n\nus-gaap:FairValueMeasurementsRecurringMember\n\n2026-03-31\n\n0001419554\n\nus-gaap:FairValueMeasurementsRecurringMember\nus-gaap:FairValueInputsLevel1Member\n\n2026-03-31\n\n0001419554\n\nus-gaap:FairValueMeasurementsRecurringMember\nus-gaap:FairValueInputsLevel2Member\n\n2026-03-31\n\n0001419554\n\nus-gaap:FairValueMeasurementsRecurringMember\nus-gaap:FairValueInputsLevel3Member\n\n2026-03-31\n\n0001419554\n\nus-gaap:WarrantMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nus-gaap:WarrantMember\n\n2025-01-01\n2025-03-31\n\n0001419554\n\nus-gaap:EmployeeStockOptionMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nus-gaap:EmployeeStockOptionMember\n\n2025-01-01\n2025-03-31\n\n0001419554\n\ncountry:US\n\n2026-01-01\n2026-03-31\n\n0001419554\n\ncountry:US\n\n2025-01-01\n2025-03-31\n\n0001419554\n\ncountry:AU\n\n2026-01-01\n2026-03-31\n\n0001419554\n\ncountry:AU\n\n2025-01-01\n2025-03-31\n\n0001419554\n\ncountry:SG\n\n2026-01-01\n2026-03-31\n\n0001419554\n\ncountry:SG\n\n2025-01-01\n2025-03-31\n\n0001419554\n\n2022-10-31\n\n0001419554\n\nus-gaap:MeasurementInputRiskFreeInterestRateMember\n\n2026-03-31\n\n0001419554\n\nus-gaap:MeasurementInputRiskFreeInterestRateMember\n\n2025-12-31\n\n0001419554\n\nBBLG:MeasurementInputExpectedVolatilityMember\n\n2026-03-31\n\n0001419554\n\nBBLG:MeasurementInputExpectedVolatilityMember\n\n2025-12-31\n\n0001419554\n\nus-gaap:MeasurementInputExpectedTermMember\n\n2026-03-31\n\n0001419554\n\nus-gaap:MeasurementInputExpectedTermMember\n\n2025-12-31\n\n0001419554\n\nBBLG:MeasurementInputExpectedDividendYieldMember\n\n2026-03-31\n\n0001419554\n\nBBLG:MeasurementInputExpectedDividendYieldMember\n\n2025-12-31\n\n0001419554\n\nBBLG:ATMAgreementMember\n\n2024-09-01\n2024-09-30\n\n0001419554\n\nBBLG:ATMAgreementMember\n\n2024-12-01\n2024-12-31\n\n0001419554\n\nBBLG:ATMAgreementMember\n\n2026-03-01\n2026-03-31\n\n0001419554\n\nBBLG:ATMAgreementMember\n\n2024-12-31\n\n0001419554\n\nBBLG:ATMAgreementMember\n\n2025-01-01\n2025-03-31\n\n0001419554\n\nBBLG:ATMAgreementMember\n\n2025-03-31\n\n0001419554\n\n2025-01-01\n2025-12-31\n\n0001419554\n\nBBLG:OctoberTwoThousandTwentyOneMember\nBBLG:ExercisableButUnexercisedCommonStockWarrantsMember\n\n2026-03-31\n\n0001419554\n\nBBLG:OctoberTwoThousandTwentyTwoMember\nBBLG:ExercisableButUnexercisedCommonStockWarrantsMember\n\n2026-03-31\n\n0001419554\n\nBBLG:OctoberTwoThousandTwentyTwoOneMember\nBBLG:ExercisableButUnexercisedCommonStockWarrantsMember\n\n2026-03-31\n\n0001419554\n\nBBLG:OctoberTwoThousandTwentyTwoTwoMember\nBBLG:ExercisableButUnexercisedCommonStockWarrantsMember\n\n2026-03-31\n\n0001419554\n\nBBLG:NovemberTwoThousandTwentyThreeMember\nBBLG:ExercisableButUnexercisedCommonStockWarrantsMember\n\n2026-03-31\n\n0001419554\n\nBBLG:NovemberTwoThousandTwentyThreeOneMember\nBBLG:ExercisableButUnexercisedCommonStockWarrantsMember\n\n2026-03-31\n\n0001419554\n\nBBLG:MarchTwoThousandTwentyFourMember\nBBLG:ExercisableButUnexercisedCommonStockWarrantsMember\n\n2026-03-31\n\n0001419554\n\nBBLG:AugustTwoThousandTwentyFourMember\nBBLG:ExercisableButUnexercisedCommonStockWarrantsMember\n\n2026-03-31\n\n0001419554\n\nBBLG:AugustTwoThousandTwentyFourOneMember\nBBLG:ExercisableButUnexercisedCommonStockWarrantsMember\n\n2026-03-31\n\n0001419554\n\nBBLG:AugustTwoThousandTwentyFourTwoMember\nBBLG:ExercisableButUnexercisedCommonStockWarrantsMember\n\n2026-03-31\n\n0001419554\n\nBBLG:JuneTwoThousandTwentyFiveMember\nBBLG:ExercisableButUnexercisedCommonStockWarrantsMember\n\n2026-03-31\n\n0001419554\n\nBBLG:JuneTwoThousandTwentyFiveOneMember\nBBLG:ExercisableButUnexercisedCommonStockWarrantsMember\n\n2026-03-31\n\n0001419554\n\nBBLG:JuneTwoThousandTwentyFiveTwoMember\nBBLG:ExercisableButUnexercisedCommonStockWarrantsMember\n\n2026-03-31\n\n0001419554\n\nBBLG:ExercisableButUnexercisedCommonStockWarrantsMember\n\n2026-03-31\n\n0001419554\n\nBBLG:TwoThousandFifteenEquityIncentivePlanMember\n\n2026-03-31\n\n0001419554\n\nBBLG:TwoThousandFifteenEquityIncentivePlanMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nus-gaap:CommonStockMember\nBBLG:EmployeesMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nus-gaap:CommonStockMember\nBBLG:EmployeesMember\n\n2025-01-01\n2025-03-31\n\n0001419554\n\nBBLG:MayTwoThousandSixteenMember\n\n2026-03-31\n\n0001419554\n\nBBLG:MayTwoThousandSixteenMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:SeptemberTwoThousandSixteenMember\n\n2026-03-31\n\n0001419554\n\nBBLG:SeptemberTwoThousandSixteenMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:JanuaryTwoThousandSeventeenMember\n\n2026-03-31\n\n0001419554\n\nBBLG:JanuaryTwoThousandSeventeenMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:JanuaryTwoThousandEighteenMember\n\n2026-03-31\n\n0001419554\n\nBBLG:JanuaryTwoThousandEighteenMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:JanuaryTwoThousandNineteenMember\n\n2026-03-31\n\n0001419554\n\nBBLG:JanuaryTwoThousandNineteenMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:OctoberTwoThousandTwentyOneMember\n\n2026-03-31\n\n0001419554\n\nBBLG:OctoberTwoThousandTwentyOneMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:JanuaryTwoThousandTwentyTwoMember\n\n2026-03-31\n\n0001419554\n\nBBLG:JanuaryTwoThousandTwentyTwoMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:AugustTwoThousandTwentyTwoMember\n\n2026-03-31\n\n0001419554\n\nBBLG:AugustTwoThousandTwentyTwoMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:SeptemberTwoThousandTwentyThreeMember\n\n2026-03-31\n\n0001419554\n\nBBLG:SeptemberTwoThousandTwentyThreeMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:JanuaryTwoThousandTwentyFourMember\n\n2026-03-31\n\n0001419554\n\nBBLG:JanuaryTwoThousandTwentyFourMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:SeptemberTwoThousandTwentyFourMember\n\n2026-03-31\n\n0001419554\n\nBBLG:SeptemberTwoThousandTwentyFourMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:OctoberTwoThousandTwentyFourMember\n\n2026-03-31\n\n0001419554\n\nBBLG:OctoberTwoThousandTwentyFourMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:JanuaryTwoThousandTwentyFiveMember\n\n2026-03-31\n\n0001419554\n\nBBLG:JanuaryTwoThousandTwentyFiveMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:JuneTwoThousandTwentyFiveMember\n\n2026-03-31\n\n0001419554\n\nBBLG:JuneTwoThousandTwentyFiveMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:JanuaryTwoThousandTwentySixMember\n\n2026-03-31\n\n0001419554\n\nBBLG:JanuaryTwoThousandTwentySixMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:LicenseAgreementMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:LicenseAgreementMember\nBBLG:FirstCommercialSaleMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:LicenseAgreementMember\nBBLG:AfterFirstCommercialSaleMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:LicenseAgreementMember\nBBLG:ThirdPartyMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:LicenseAgreementMember\nBBLG:UniversityOfCaliforniaLosAngelesTechnologyDevelopmentGroupMember\nsrt:MinimumMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:LicenseAgreementMember\nBBLG:UniversityOfCaliforniaLosAngelesTechnologyDevelopmentGroupMember\nsrt:MaximumMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:UniversityOfCaliforniaLosAngelesTechnologyDevelopmentGroupMember\nBBLG:LicenseAgreementMember\nBBLG:FirstSubjectInFeasibilityStudyMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:LicenseAgreementMember\nBBLG:UniversityOfCaliforniaLosAngelesTechnologyDevelopmentGroupMember\nBBLG:FirstSubjectInPivotalStudyMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:LicenseAgreementMember\nBBLG:UniversityOfCaliforniaLosAngelesTechnologyDevelopmentGroupMember\nBBLG:PreMarketApprovalOfLicensedProductOrLicensedMethodMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:LicenseAgreementMember\nBBLG:UniversityOfCaliforniaLosAngelesTechnologyDevelopmentGroupMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:LicenseAgreementMember\nBBLG:UniversityOfCaliforniaLosAngelesTechnologyDevelopmentGroupMember\nBBLG:ScenarioOneMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:LicenseAgreementMember\nBBLG:UniversityOfCaliforniaLosAngelesTechnologyDevelopmentGroupMember\nBBLG:ScenarioTwoMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:LicenseAgreementMember\nBBLG:UniversityOfCaliforniaLosAngelesTechnologyDevelopmentGroupMember\nBBLG:ScenarioThreeMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:UniversityOfCaliforniaLosAngelesTechnologyDevelopmentGroupMember\n\n2026-01-01\n2026-03-31\n\n0001419554\n\nBBLG:UniversityOfCaliforniaLosAngelesTechnologyDevelopmentGroupMember\nBBLG:LicenseAgreementMember\n\n2025-01-01\n2025-03-31\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure\n\n \n\n \n\n \n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington,\nD.C. 20549**\n\n \n\n**FORM\n10-Q**\n\n \n\n(Mark\nOne)\n\n \n\n☒\nQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\n**For\nthe quarterly period ended March 31, 2026**\n\n \n\n☐\nTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\nFor\nthe transition period from _________ to _________\n\n \n\nCommission\nFile No. **001-40899**\n\n \n\n**Bone\nBiologics Corporation**\n\n(Exact\nname of registrant as specified in its charter)\n\n \n\n**Delaware**\n \n**42-1743430**\n\n(State\nor other jurisdiction of\n\nincorporation\nor formation)\n\n \n\n(I.R.S.\nemployer\n\nidentification\nnumber)\n\n \n\n**2\nBurlington Woods Drive, Ste 100, Burlington, MA 01803**\n\n(Address\nof principal executive offices and Zip Code)\n\n \n\n**(781)\n552-4452**\n\n(Registrant’s\ntelephone number, including area code)\n\n \n\nSecurities\nregistered pursuant to Section 12(b) of the Act:\n\n \n\n**Title\nof each class**\n \n**Trading\nSymbol(s)**\n \n**Name\nof each exchange on which registered**\n\nCommon\nstock, $0.001 par value per share\n \n**BBLG**\n \n**The\nNasdaq Capital Market**\n\nWarrants\nto Purchase Common stock, $0.001 par value per share\n \n**BBLGW**\n \n**The\nNasdaq Capital Market**\n\n \n\n \n\nIndicate\nby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange\nAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)\nhas been subject to such filing requirements for the past 90 days.\n\n \n\n☒\nYes ☐ No\n\n \n\nIndicate\nby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule\n405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant\nwas required to submit and post such files).\n\n \n\n☒\nYes ☐ No\n\n \n\nIndicate\nby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting\ncompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”\n“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge\naccelerated filer\n☐\nAccelerated\nfiler\n☐\n\nNon-accelerated\nfiler\n☒\nSmaller\nreporting company\n☒\n\n \n \nEmerging\ngrowth company\n☐\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate\nby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).\n\n \n\n☐\nYes ☒ No\n\n \n\nAs\nof May 14, 2026, there were 1,795,260 shares of the issuer’s common stock, $0.001 par value, outstanding.\n\n \n\n \n\n \n\n \n\n \n\n \n\n**Bone\nBiologics Corporation**\n\n**-\nINDEX -**\n\n \n\n \nPage\n\n**PART I – FINANCIAL INFORMATION:**\n \n\n \n \n\n[Item 1. Financial Statements.](#a_002)\nF-1\n\n \n \n\nUnaudited\nCondensed Consolidated Financial Statements\n \n\n \n \n\n[Unaudited Condensed Consolidated Balance Sheets](#a_003)\nF-1\n\n \n \n\n[Unaudited Condensed Consolidated Statements of Operations](#a_004)\nF-2\n\n \n \n\n[Unaudited Condensed Consolidated Statements of Stockholders’ Equity](#a_005)\nF-3\n\n \n \n\n[Unaudited Condensed Consolidated Statements of Cash Flows](#a_006)\nF-5\n\n \n \n\n[Notes to Unaudited Condensed Consolidated Financial Statements](#a_007)\nF-6\n\n \n \n\n[Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations](#a_008)\n4\n\n \n \n\n[Item 3. Quantitative and Qualitative Disclosures about Market Risk](#a_009)\n7\n\n \n \n\n[Item 4. Controls and Procedures](#a_010)\n7\n\n \n \n\n**PART II – OTHER INFORMATION:**\n8\n\n \n \n\n[Item 1. Legal Proceedings](#a_012)\n8\n\n \n \n\n[Item 1A. Risk Factors](#a_013)\n8\n\n \n \n\n[Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#a_014)\n8\n\n \n \n\n[Item 3. Defaults Upon Senior Securities](#a_015)\n8\n\n \n \n\n[Item 4. Mine Safety Disclosures](#a_016)\n8\n\n \n \n\n[Item 5. Other Information](#a_017)\n8\n\n \n \n\n[Item 6. Exhibits](#a_018)\n9\n\n \n \n\n[Signatures](#a_020)\n10\n\n \n\n2\n\n \n\n \n\n**NOTE\nON FORWARD-LOOKING STATEMENTS**\n\n \n\nThis\nQuarterly Report on Form 10-Q (this “Form 10-Q”) contains forward-looking statements. Such forward-looking statements include\nthose that express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements\nof historical fact. These forward-looking statements are based on our current expectations and projections about future events and they\nare subject to risks and uncertainties known and unknown that could cause actual results and developments to differ materially from those\nexpressed or implied in such statements. These forward-looking statements are subject to a number of risks, uncertainties and assumptions.\nFor a more detailed listing of some of the risks and uncertainties facing the Company, please see our Annual Report on Form 10-K for\nthe fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 2, 2026 and subsequent\nQuarterly Reports on Form 10-Q or other reports filed with the SEC.\n\n \n\nAll\nstatements other than historical facts contained in this report, including statements regarding our future financial position,\ncapital expenditures, cash flows, business strategy and plans and objectives of management for future operations are forward-looking\nstatements. The words “anticipate,” “believe,” “expect,” “future,”\n“plan,” “estimate,” “can,” “could,” “may,” “might,”\n“will,” “would,” and similar expressions are intended to identify forward-looking statements. These\nstatements include, among others, information regarding future operations, future capital expenditures, and future net cash flow.\nSuch statements reflect our management’s current views with respect to future events and financial performance and involve\nrisks and uncertainties, including, without limitation, our ability to raise additional capital to fund our operations, inflation,\nrising interest rates, governmental responses there to and possible recession caused thereby, obtaining Food and Drug Administration\nand other regulatory authorization to market our drug and biological products, successful completion of our clinical trials, our\nability to achieve regulatory authorization to market our lead product NELL-1/DBM, the success of our patent application, our\nreliance on third party manufacturers for our drug products, market acceptance of our products, our dependence on licenses for\ncertain of our products, our reliance on the expected growth in demand for our products, exposure to product liability and defect\nclaims, development of a public trading market for our securities, and various other matters, many of which are beyond our\ncontrol.\n\n \n\nShould\none or more of these risks or uncertainties occur, or should underlying assumptions prove to be incorrect, actual results may vary materially\nand adversely from those anticipated, believed, estimated or otherwise indicated. Consequently, all of the forward-looking statements\nmade in this Form 10-Q are qualified by these cautionary statements and accordingly there can be no assurances made with respect to the\nactual results or developments. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking\nstatements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such\nforward-looking statements.\n\n \n\nUnless\nexpressly indicated or the context requires otherwise, the terms “Company,” “we,” “us,” and “our”\nin this document refer to Bone Biologics Corporation, a Delaware corporation and its wholly owned subsidiary as defined under the heading\n“Management’s Discussion and Analysis” in this Form 10-Q.\n\n \n\n3\n\n \n\n \n\n**PART\nI – FINANCIAL INFORMATION**"}